Akari Therapeutics Plc — Director's Dealing 2015

Jan 2, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celsus Therapeutics Plc. (CLTX)
CIK: 0001541157
Period of Report: 2015-01-01

Reporting Person: Elefant Dov (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Ordinary Shares	$1.56	2022-01-11	Ordinary Shares (40000)		Direct
Options to Purchase Ordinary Shares	$2.00	2023-07-01	Ordinary Shares (100000)		Direct
Options to Purchase Ordinary Shares	$0.75	2024-02-05	Ordinary Shares (40000)		Direct

Footnotes

F1: 100% of the shares underlying the options vested on 1/11/2013.

F2: 100% of the shares underlying the options vested on 7/1/2014.

F3: 100% of the shares underlying the options vested on 5/31/2014.